Agios Pharmaceuticals: Worthy Of Accumulation
Source: SeekingAlpha
2026-03-09 11:34:33 ET
When I last looked at Agios Pharmaceuticals ( AGIO ) in mid-June of last year, I concluded that article noting that Agios had a fortress balance sheet. The stock merited a ' Speculative Buy ' rating for risk-tolerant investors. The shares moved up impressively into a key FDA approval late in 2024 and then fell off a cliff due to some recent trial results....
Read the full article on Seeking Alpha
For further details see:
Agios Pharmaceuticals: Worthy Of Accumulation
Agios Pharmaceuticals Inc.
NASDAQ: AGIO
AGIO Trading
2.16% G/L:
$28.61 Last:
125,350 Volume:
$28.51 Open:
AGIO Latest News
March 10, 2026 09:00:00 am
Agios Pharmaceuticals, Inc. Investigated Regarding Potential Securities Law Violations - Contact The Gross Law Firm for Details- AGIO
March 03, 2026 09:00:00 am
Agios Pharmaceuticals, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact The Gross Law Firm Regarding Potential Securities Law Violations - AGIO
March 02, 2026 07:00:00 am
Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates
February 23, 2026 10:57:17 am
From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer
AGIO Stock Data
$1,577,971,753
55,806,318
0.06%
106
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
